Drugs & Targets Blenrep receives FDA approval in relapsed or refractory multiple myeloma September 04, 2020Vol.46 No.33
Drugs & Targets Guardant360 CDx assay receives FDA approval as first liquid biopsy NGS companion diagnostic test September 04, 2020Vol.46 No.33
Drugs & Targets ClonoSEQ assay receives expanded FDA clearance to assess MRD in CLL September 04, 2020Vol.46 No.33
Drugs & Targets Melflufen receives FDA Priority Review for triple-class refractory multiple myeloma September 04, 2020Vol.46 No.33
Drugs & Targets FDA to evaluate cancer therapies in patients with brain metastases September 04, 2020Vol.46 No.33
Drugs & Targets FDA updates analysis of medical device reports of breast implant illness and breast implant-associated lymphoma September 04, 2020Vol.46 No.33
Drugs & Targets Dragonfly Therapeutics, BMS agree to exclusive global license for IL-12 investigational immunotherapy program September 04, 2020Vol.46 No.33
Drugs & Targets Thermo Fisher Scientific, Hengrui Therapeutics to develop companion diagnostic in NSCLC indication September 04, 2020Vol.46 No.33
Clinical Roundup NCCS survivorship data demonstrates prevailing “doctor knows best” mindset September 04, 2020Vol.46 No.33
Clinical Roundup Phase III VIALE-A trial of venetoclax combination meets OS endpoint in AML September 04, 2020Vol.46 No.33
